Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

AMGEN

(AMGN)
  Report  
Delayed Quote. Delayed Nasdaq - 08/16 04:00:00 pm
204.02 USD   +2.36%
08/14AMGEN : Board of Directors Tours Company Labs in San Francisco
PU
08/14AMGEN : Foundation Honors David Baltimore With Gift to Caltech
PU
08/14AMGEN : Ex-dividend day for
FA
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Amgen : Board of Directors Tours Company Labs in San Francisco

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/14/2019 | 06:17pm EDT

From the moment our Board of Directors entered the Amgen labs in South San Francisco, affectionately known as the 'Birthplace of Biotech,' you could see their collective enthusiasm for the science and the possibility it holds for patients.

The Amgen South San Francisco facility is home to researchers pushing the boundaries of science in order to pursue transformative new treatments for serious illnesses like cancer, heart disease and metabolic disease. Flavius Martin, Vice President, Oncology and Inflammation Discovery Research, and other R&D leaders hosted the visit, giving the Board an update on Amgen's R&D progress.

Disclaimer

Amgen Inc. published this content on 14 August 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 August 2019 22:16:07 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMGEN
08/14AMGEN : Board of Directors Tours Company Labs in San Francisco
PU
08/14AMGEN : Foundation Honors David Baltimore With Gift to Caltech
PU
08/14AMGEN : Ex-dividend day for
FA
08/12Health Care Down, But Losses Limited by Lack of Cyclical Exposure -- Health C..
DJ
08/12Amgen and Sysco rise while Viacom and Bank of America fall
AQ
08/12NOVARTIS : Sandoz will appeal District Court of New Jersey ruling in biosimilar ..
AQ
08/12AMGEN : Wins Patent Case on Enbrel
AQ
08/09Wall Street ends down amid more trade woes, high volatility
RE
08/09Canada enacts drug price crackdown, in blow to pharmaceutical industry
RE
08/09AMGEN : Wins Patent Case On Enbrel® (etanercept)
PR
More news
Financials (USD)
Sales 2019 22 830 M
EBIT 2019 10 915 M
Net income 2019 7 711 M
Debt 2019 2 336 M
Yield 2019 2,84%
P/E ratio 2019 16,1x
P/E ratio 2020 15,1x
EV / Sales2019 5,46x
EV / Sales2020 5,26x
Capitalization 122 B
Chart AMGEN
Duration : Period :
Amgen Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 209,76  $
Last Close Price 204,02  $
Spread / Highest target 13,2%
Spread / Average Target 2,81%
Spread / Lowest Target -15,2%
EPS Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline CFO, Chief Accounting Officer & Executive VP
David M. Reese Executive Vice President-Research & Development
Frank C. Herringer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN2.38%119 526
JOHNSON & JOHNSON1.15%344 517
ROCHE HOLDING LTD.12.24%235 575
ROCHE HOLDING13.20%235 575
MERCK AND COMPANY11.32%213 689
NOVARTIS17.81%202 958